37 patents
Utility
Crystal forms and production methods thereof
26 Sep 23
The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same.
John R. Snoonian, Harold Scott Wilkinson, Haitao Zhang
Filed: 19 May 22
Utility
Modified release formulations and uses thereof
23 May 23
Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.
Takumi Asada, Gerald R. Galluppi, Seth Cabot Hopkins, Megumi Maruyama, Siriporn Toongsuwan, Yuki Tsushima
Filed: 30 Sep 21
Utility
Nonracemic mixtures and uses thereof
6 Dec 22
Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.
Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
Filed: 13 Nov 20
Utility
Heteroaryl-isochroman compounds and uses thereof
8 Nov 22
Carrie A. Bowen, Douglas F. Burdi, Michele L. R. Heffernan, Lee W. Herman, Linghong Xie
Filed: 12 Aug 20
Utility
Salts, crystal forms, and production methods thereof
13 Sep 22
Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same.
Andrea Bauer, Nandkumar Nivritti Bhogle, Xiaoxia Chen, Shahla Jamzad, Robert Joseph Prytko, Kostas Saranteas, Michael Joseph Sizensky, Harold Scott Wilkinson, Haitao Zhang
Filed: 28 Aug 20
Utility
Sublingual films
23 Aug 22
The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
Nathan John Bryson, Anthony John Giovinazzo, Scott David Barnhart, Michael Clinton Koons
Filed: 10 May 19
Utility
Nebulizer monitoring device, system and method
9 Aug 22
Described herein are devices, systems and methods for monitoring the use of a nebulized medication, such as can be administered using a nebulizer.
Michael Segal, Nathan Abel, Spencer Brown, Everett Crosland, Francisco Javier de Ana Arbeloa, Thomas Goodin, Joseph Gordon, Michael Metz, Daniel Nelson, Jae Hong Park, Sean Scanlon, Janis Skujins, Jennet Toyjanova
Filed: 22 Apr 19
Utility
Heteroaryl compounds and methods of use thereof
17 May 22
Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use.
John Emmerson Campbell, Una Campbell, Taleen G. Hanania, Liming Shao
Filed: 20 Dec 19
Utility
Easy-open peel pouch
26 Apr 22
Embodiments include a package for containing and dispensing a product.
Julie A. Cardin, Edward Emmett Chapdelaine, Steven A. Rau
Filed: 23 Sep 20
Utility
1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders
7 Dec 21
Linghong Xie, Philip Glyn Jones, Kerry L. Spear, Noel Aaron Powell, Taleen G. Hanania, Vadim Alexandrov
Filed: 6 May 19
Utility
Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
30 Nov 21
Michele L. R. Heffernan, Larry Wendell Hardy, Scott P. Brown, Lee W. Herman
Filed: 4 Aug 16
Utility
Modified release formulations and uses thereof
2 Nov 21
Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.
Takumi Asada, Gerald R. Galluppi, Seth Cabot Hopkins, Megumi Maruyama, Siriporn Toongsuwan, Yuki Tsushima
Filed: 4 Jun 20
Utility
Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
5 Oct 21
The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
Nandkumar Nivritti Bhogle, Takahiko Hashizuka, Robert Joseph Prytko, John R. Snoonian, Harold Scott Wilkinson, Haitao Zhang
Filed: 13 Mar 20
Utility
Methods of treating schizophrenia
28 Sep 21
Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia.
Seth Hopkins, Kenneth Koblan, Antony Loebel, Ajay Ogirala
Filed: 16 Feb 18
Utility
Compounds and compositions and uses thereof
3 Aug 21
Vadim Alexandrov, Carrie A. Bowen, Taleen G. Hanania, Noel Aaron Powell
Filed: 28 Jul 17
Utility
Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
20 Jul 21
The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
Nandkumar Nivritti Bhogle, Takahiko Hashizuka, Robert Joseph Prytko, John R. Snoonian, Harold Scott Wilkinson, Haitao Zhang
Filed: 13 Mar 20
Utility
Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa
30 Mar 21
Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described.
Scott David Barnhart, Michael Clinton Koons, Madhu Sudan Hariharan, Jordan Dubow, Thierry Bilbault, Anthony John Giovinazzo
Filed: 9 Sep 19
Utility
Compounds and compositions and uses thereof
23 Feb 21
Linghong Xie, Michele L. R. Heffernan, Philip Glyn Jones, Taleen G. Hanania
Filed: 10 Dec 18
Utility
Multicyclic compounds and methods of use thereof
19 Jan 21
Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use.
Liming Shao, John Emmerson Campbell, Michael Charles Hewitt, Una Campbell, Taleen G. Hanania
Filed: 14 Feb 20
Utility
Nonracemic mixtures and uses thereof
28 Dec 20
Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.
Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
Filed: 12 Apr 20